Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Ricklie Julian
Assistant Professor, Medicine - (Clinical Scholar Track)
Medicine
Overview
Research
More
Collaboration
(14)
Jennifer Segar
Mutual work: 8 Grants
Collaboration Details
Lizeth Evangelista
Mutual work: 7 Grants
Collaboration Details
Carlos Caulin
Mutual work: 2 Publications
Collaboration Details
Denise Roe
Mutual work: 2 Publications
Collaboration Details
Audrey Baker
Mutual work: 1 Publication
Collaboration Details
Page 1 of 3
Previous page
Next page
Grants
(21)
A Phase 1, Multi-center, Open Label First-in-Human Study with ABBV-CLS-579 Alone and in Combination in Subjects with Locally Advanced or Metastatic Tumors
Active
·
2023
·
$0 / $830.5K
·
External
Co-Investigator (COI)
oncology,
clinical trials,
cancer treatment,
drug development,
immunotherapy
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study of IO-202 in Combination with Pembrolizumab in Subjects with Advanced, Relapsed, or Refractory Solid Tumors
Active
·
2023
·
$0 / $391.4K
·
External
Co-Investigator (COI)
immunotherapy,
cancer,
clinical trial,
combination therapy,
solid tumors
Phase 1 Study of Intratumoral Administration of VAX014 in Subjects with Advanced Solid Tumors
Active
·
2023
·
$0 / $352.4K
·
External
Co-Investigator (COI)
cancer immunotherapy,
clinical trial,
tumor microenvironment,
intratumoral therapy,
solid tumors
A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients wi
Active
·
2023
·
$0 / $245.9K
·
External
Co-Investigator (COI)
immunotherapy,
oncology,
viral therapy,
clinical trial,
safety
A Phase 1/1b Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of KIN-3248 in Participants with Advanced Tumors Harbori
Active
·
2023
·
$0 / $216.2K
·
External
Co-Investigator (COI)
oncology,
pharmacokinetics,
pharmacodynamics,
clinical trial,
safety
Page 1 of 5
Previous page
Next page
Publications
(6)
Recent
The impact of socioeconomic and geographic factors on access to transoral robotic/endoscopic surgery for early stage oropharyngeal malignancy
2022
socioeconomic factors,
geographic factors,
transoral robotic surgery,
endoscopic surgery,
oropharyngeal malignancy
Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
2022
Immunotherapy Approaches in HPV-Associated Head and Neck Cancer
2021
Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic R/M) head and neck squamous cell carcinoma HNSCC)
2020
cancer,
immunotherapy,
clinical trial,
targeted therapy,
biological drugs
2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer
2019
Outcomes of advanced pulmonary large cell neuroendocrine carcinoma stratified by RB1 loss, SLFN11 expression, and tumor mutational burden.
2018